Dexcom (DXCM) Depreciation & Amortization (CF) (2010 - 2026)

Dexcom (DXCM) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $67.1 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 11.83% year-over-year to $67.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258.9 million (up 14.96% YoY) and the FY2025 annual result came in at $251.8 million, up 15.66% from the prior year.
• Depreciation & Amortization (CF) grew to $67.1 million in Q1 2026 per DXCM's latest filing, from $65.2 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $67.1 million in Q1 2026 and bottomed at $36.3 million in Q4 2022.
• The 5-year median for Depreciation & Amortization (CF) is $52.5 million (2023), against an average of $51.7 million.
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) jumped 85.53%; it then advanced 0.23% in 2023.
• Tracing DXCM's Depreciation & Amortization (CF) over 5 years: stood at $36.3 million in 2022, then jumped by 44.63% to $52.5 million in 2023, then grew by 10.1% to $57.8 million in 2024, then increased by 12.8% to $65.2 million in 2025, then rose by 2.91% to $67.1 million in 2026.
• Per Business Quant, the three latest DXCM Depreciation & Amortization (CF) figures stand at $67.1 million (Q1 2026), $65.2 million (Q4 2025), and $63.6 million (Q3 2025).

Peer Comparison